Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Die Diabetologie
Erschienen in: Der Diabetologe 3/2017

21.04.2017 | Typ-1-Diabetes | Leitthema

Aktueller Stand der klassischen Insulinpumpentherapie

verfasst von: Dr. T. Siegmund, A. Thomas

Erschienen in: Die Diabetologie | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Zusammenfassung

Insulinpumpentherapie

Die subkutane Insulinpumpentherapie (CSII) stellt die zurzeit physiologischste Form der Insulinzufuhr dar. Patienten mit Typ-1-Diabetes profitieren besonders von einer Verbesserung des HbA1c-Werts (HbA1c: Glykohämoglobin Typ A1c), der Abnahme der Häufigkeit von Hypoglykämien und geringeren Glukoseschwankungen. Die optimierte Glukosekontrolle kann das Risiko für diabetische Folgeerkrankungen reduzieren.

Sensorunterstützte Pumpentherapie

Die CSII liefert eine optimale Basis zur Koppelung mit kontinuierlich messenden Glukosesensoren (CGM). Diese sensorunterstützte Pumpentherapie (SuP) ist ein Schritt hin zu einem bereits in naher Zukunft verfügbaren geschlossenen System, der künstlichen Bauchspeicheldrüse.
Literatur
1.
Hepp KD, Renner R, von Funcke HJ et al (1977) Glucose homeostasis under continous intravenous insulon therapy in diabetics. Horm Metab Res 7:72–76PubMed
2.
3.
Pickup JC, Keen H, Parsons JA et al (1979) Continuous subcutaneous insulin infusion:good blood glucose control for up to 4 days. Diabetologia 16:385–389CrossRefPubMed
4.
Mecklenburg RS, Benson JW, Becker NM et al (1982) Clinical use of the insulin infusion pump in 100 patients with type 1 diabetes. N Engl J Med 307:513–518CrossRefPubMed
5.
Koivisto VA, Yki-Jarvinen H, Helve E et al (1986) Pathogenesi and prevention of the dawn phenomenon in diabetic patients treated with CSII. Diabetes 35:78–82CrossRefPubMed
6.
Chantelau E, Spraul M, Mühlhauser I et al (1989) Long-term safety, efficacy and side effects of continuous subcutaneous insulin infusion treatment for type 1 (insulin-dependent) diabetes mellitus: a one centre experience. Diabetologia 32:421–426CrossRefPubMed
7.
Linkeschova R, Raoul M, Bott U et al (2002) Less severe hypoglycaemia, better metabolic control, and improved quality of life in Type 1 diabetes mellitus with continuous subcutaneous insulin infusion (CSII) therapy; an observational study of 100 consecutive patients followed for a mean of 2 years. Diabet Med 19:746–751CrossRefPubMed
8.
Bode BW, Steed RD, Davidson PC (1996) Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type 1 diabetes. Diabetes Care 19:324–327CrossRefPubMed
9.
Boland EA, Grey M, Oesterle A et al (1999) Continuous subcutaneous insulin infusion. A new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes. Diabetes Care 22:1799–1784CrossRef
10.
Maniatis AK, Klingensmith GJ, Slover RH et al (2001) Continuous subcutaneous insulin infusion therapy for children and adolescents: an option for routine diabetes care. Pediatrics 107(2):351–356CrossRefPubMed
11.
Dahl-Jorgensen K, Brinchmann-Hansen O et al (1985) Rapid tightening of blood glucose control leads to transient deterioration of retinopathy in insulin dependent diabetes mellitus: the Oslo study. BMJ 290:811–815CrossRefPubMedPubMedCentral
12.
Dahl-Jorgensen K, Brinchmann-Hansen O, Hanssen KF (1986) Effect of near normoglycaemia for two years on progression of early diabetic retinopathy, nephropathy, and neuropathy: the Oslo study. BMJ 293:1195–1199CrossRefPubMedPubMedCentral
13.
Lüddeke HJ, Hofmann W, Guder WG et al (2002) Urinary albumin concentrationin 52 CSII treated type 1 diabetic patients during a follow-up of 4 years. Diabetes Stoffwechs 11(Suppl. 1):115
14.
Aragona M, Giannarelli R, Coppelli A et al (2003) Improvement of retinopathy in Type 1 diabetic patients treated with continuous subcutaneous insulin infusion (CSII). Diabetes Metab 29(4):S235
15.
Danne T, von Schütz W, Lange K et al (2006) Current practice of insulin pump therapy in children and adolescents – the Hannover recipe. Pediatr Diabetes 7(Suppl. 4):25–31CrossRefPubMed
16.
17.
Kordonouri O, Hartmann R, Lauterborn R et al (2006) Age-specific advantages of continuous subcutaneous insulin infusion as compared with multiple daily injections in pediatric patients. Diabetes Care 29(1):133–134CrossRefPubMed
18.
Vortherms J, Klinkert Ch, Lotz N et al (2001) Insulinpumpentherapie bei Kindern und Jugendlichen mit schwerwiegenden Verhaltensauffälligkeiten. Diabetes Stoffw 10(Suppl.1):56
19.
Knight S, Northam E, Donath S et al (2009) Improvements in cognition, mood and behaviour following commencement of continuous subcutaneous insulin infusion therapy in children with type 1 diabetes mellitus: a pilot study. Diabetologia 52:193–198CrossRefPubMed
20.
Berghaeuser MA, Kapellen T, Heidtmann B et al (2008) Continuous subcutaneous insulin infusion in toddlers starting at diagnosis of type 1 diabetes mellitus. A multicenter analysis of 104 patients from 63 centres in Germany and Austria. Pediatr Diabetes 9:590–595CrossRefPubMed
21.
Holder M, Ludwig-Seibold C, Lilienthal E et al (2007) Trends in der Insulinpumpentherapie bei Kindern, Jugendlichen und jungen Erwachsenen mit Typ-1-Diabetes von 1995–2006: Daten der DPV-Initiative. Diabetol Stoffwechs 2:169–174CrossRef
22.
Chase HP, Saib SZ, MacKenzie T et al (2002) Post-prandial glucose excursions following four methods of bolus insulin administration in subjects with Type 1 diabetes. Diabet Med 19:317–321CrossRefPubMed
23.
Gross TM, Kayne D, King A et al (2003) A bolus calculator is an effective means of controlling postprandial glycemia in patients on insulin pump therapy. Diabetes Technol Ther 5:365–369CrossRefPubMed
24.
Danne T, Reichel A, Liebl A et al (2006) First user experience with an integrated insulin pump and real-time continuous glucose monitoring system in German patients with type 1 diabetes. Diabetes 55(Suppl. 1):A194–A195
25.
Ly TT, Nicholas JA, Retterath A et al (2013) Effect of sensor-augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy in patients with type 1 diabetes. A randomized clinical trial. JAMA 310(12):1240–1247CrossRefPubMed
26.
Danne T, Tsioli C, Kordonouri O et al (2014) The PILGRIM study: in silico modeling of a predictive low glucose management system and feasibility in youth with type 1 diabetes during exercise. Diabetes Technol Ther 16(6):338–347CrossRefPubMed
27.
Bergenstal RM, Garg S, Weinzimer SA, Buckingham BA, Bode BW, Tamborlane WV, Kaufman FR (2016) Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. JAMA 316(13):1407–1408CrossRefPubMed
28.
Dehais J, Anthimopoulos M, Shevchik S et al (2014) A prototype system for carbohydrate content estimation based on computer vision method. Diabetes Technol Ther 16(Suppl 1):A108–A109
29.
Heise T, Hövelmann U, Brøndsted L, Adrian CL, Nosek L, Haahr H (2015) Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart. Diabetes Obes Metab 17(7):682–688CrossRefPubMedPubMedCentral
30.
Heise T, Zijlstra E, Nosek L, Rikte T, Haahr H (2017) Pharmacological properties of faster-acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: a randomized, double-blind, crossover trial. Diabetes Obes Metab 19(2):208–215CrossRefPubMed
31.
Hilderbrandt P, Birch K, Jensen FM et al (1985) Absorption of subcutaneously infused insulin: influence of basal rate pulse interval. Diabetes Care 8:287–290CrossRef
32.
Heinemann L, Nosek L, Kapitza C et al (2009) Changes in basal insulin infusion rates with subcutaneous insulin infusion: time until a change in metabolic effect is induced in patients with type 1 diabetes. Diabetes Care 32(8):1437–1439CrossRefPubMedPubMedCentral
33.
Pankowska E, Blazik M, Groele L (2012) Does the fat-protein meal increase postprandial glucose level in type 1 diabetes patients on insulin pump: the conclusion of a randomized study. Diabetes Technol Ther 14(1):16–22CrossRefPubMed
34.
Jones SM, Quarry JL, Caldwell-McMillan M et al (2005) Optimal insulin pump dosing and postprandial glycemia following a pizza meal using the continuous glucose monitoring system. Diabetes Technol Ther 7:233–240CrossRefPubMed
35.
Kordonouri O, Hartmann R, Remus K et al (2012) Benefit of supplementary fat plus protein counting as compared with conventional carbohydrate counting for insulin bolus calculation in children with pump therapy. Pediatr Diabetes 13(7):540–544CrossRefPubMed
36.
Shashaj B, Busetto E, Sulli N (2008) Benefits of a bolus calculator in pre- and postprandial glycaemic control and meal flexibility of paediatric patients using continuous subcutaneous insulin infusion (CSII). Diabet Med 25:1036–1042CrossRefPubMed
37.
Ziegler R, Cavan DA, Cranston I et al (2013) Use of an insulin bolus advisor improves glycemic control in multiple daily insulin injection (MDI) therapy patients with suboptimal glycemic control: first results from the ABACUS trial. Diabetes Care 36(11):3613–3619CrossRefPubMedPubMedCentral
38.
Siegmund T, Kolassa R, Thomas A (2011) Sensorunterstützte Therapie (SuP) und Sensorunterstützte Pumpentherapie (SuP). Unimed Science, Bremen. ISBN 978-3837412321
39.
Rudolph JW, Hirsch IB (2002) Assessment of therapy with continuous subcutaneous insulin infusion in an academic diabetes clinic. Endocr Pract 8:401–405CrossRefPubMed
40.
5-Nations Study Group, Hoogma RPL, Hammond PJ, Gomis R et al (2005) Comparison of the effects continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5‑nations trial. Diabetes Med 23:141–147
41.
Doyle EA, Weinzimer SA, Steffen AT et al (2004) A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injection using insulin glargine. Diabetes Care 27:1554–1558CrossRefPubMed
42.
Heptulla RA, Allen HF, Gross TM et al (2004) Continuous glucose monitoring in children with type 1 diabetes: before and after insulin pump therapy. Pediatr Diabetes 5:10–15CrossRefPubMed
43.
Pickup JC, Kidd J, Burmiston D et al (2005) Effectiveness of continuous subcutaneous insulin infusion in hypoglycaemia-prone type 1 diabetes. Pract Diabetes Int 22:10–14CrossRef
44.
Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R (2003) Insulin pump therapy: a meta-analysis. Diabetes Care 26:1079–1087CrossRefPubMed
45.
Jeitler K, Horvath K, Berghold A et al (2008) Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis. Diabetologia 51:941–951CrossRefPubMed
46.
Pickup J, Sutten AJ (2008) Severe hypoglycaemia and glycaemic control in Type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med 25:765–774CrossRefPubMed
47.
The Diabetes Control and Complications Trial Research Group (1997) Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes 46:271–286CrossRef
48.
Bode B (2006) Pump therapy. Diabet Med 23(Suppl. 4):426–427
49.
Bode BW, Steed RD, Davidson PC (1996) Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type 1 diabetes. Diabetes Care 19:324–327CrossRefPubMed
50.
Aragona M, Giannarelli R, Coppelli A et al (2003) Improvement of retinopathy in Type 1 diabetic patients treated with continuous subcutaneous insulin infusion (CSII). Diabetes Metab 29(4):S235
51.
Austenat E, Würzner M, Semmler S et al (2006) CSII is superior to MDI for type 1 diabetes under real world conditions in clinical endpoints. Diabetes 55(Suppl. 1):A459
52.
53.
Pickup J, Mattock M, Kerry S (2002) Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomized controlled trials. BMJ 324:1–6CrossRef
54.
Monnier L, Mas E, Ginet C et al (2006) Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 295:1681–1687CrossRefPubMed
55.
Ceriello A, Kumar S, Piconi L et al (2007) Simultaneous control of hyperglycemia and oxidative stress normalizes endothelial function in type 1 diabetes. Diabetes Care 30:649–654CrossRefPubMed
56.
Monnier L, Colette C, Leiter L et al (2007) The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care 30:185–186CrossRefPubMed
57.
Hirsch IB, Brownlee M (2005) Should minimal blood glucose variability become the gold standard of glycemic control? J Diabetes Complicat 19:178–181CrossRefPubMed
58.
Schreiver C, Jacoby U, Thomas A et al (2013) Glycaemic variability in paediatric patients with type 1 diabetes on continuous subcutaneous insulin infusion (CSII) or multiple daily injections (MDI): a cross-sectional cohort study. Clin Endocrinol (Oxf) 79:641–647
59.
Pickup J, Keen H (2002) Continuous subcutaneous insulin infusion at 25 years: evidence base for the expanding use of insulin pump therapy in type 1 diabetes. Diabetes Care 25:593–598CrossRefPubMed
60.
Lauritzen T, Pramming S, Deckert T et al (1983) Pharmacokinetics of continuous subcutaneous insulin infusion. Diabetologia 24:326–329CrossRefPubMed
61.
Heise T, Nosek L, Biilmann Ronn B et al (2004) Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 53:1614–1620CrossRefPubMed
62.
Liebl A, Krinelke L (2003) Long-term results of insulin pump therapy (CSII) in adolescents and adults with type 1 diabetes mellitus in Germany. Diabetol Polska 10:179–185
63.
The EQuality1 Study Group (2008) Quality of life and treatment satisfaction in adults with Type 1 diabetes: a comparison between continuous subcutaneous insulin infusion and multiple daily injections. Diabet Med 25:213–220CrossRef
64.
Schottenfeld-Naor Y, Galatzer A, Karp M et al (1985) Comparison of metabolic and psychological parameters during continuous subcutaneous insulin infusion and intensified conventional insulin treatment in type I diabetic patients. Isr J Med Sci 21:822–828PubMed
65.
Shapiro J, Wigg D, Charles MA et al (1984) Personality and family profiles of chronic insulin-dependent diabetic patients using portable insulin infusion pump therapy: a preliminary investigation. Diabetes Care 7:137–142CrossRefPubMed
66.
Cyganek K, Hebda-Szydlo A, Katra B et al (2009) Efficacy and safety of continuous subcutaneous insulin infusion therapy in pregnancy complicated by type 1 diabetes. Diabetes 58(Suppl. 1):A466–A467
67.
Cyganek K, Katra B, Skupien J et al (2010) Glycemic control and selected pregnancy outcomes in type 1 diabetes women on continuous subcutaneous insulin infusion and multiple daily injections: the significance of pregnancy planning. Diabetes Technol Ther 12(1):41–47CrossRefPubMed
68.
Jovanovic L, Knopp RH, Kim H et al (2005) Elevated pregnancy losses at high and low extremes of maternal glucose in early normal and diabetic pregnancy: evidence for a protective adaptation in diabetes. Diabetes Care 28:1113–1117CrossRefPubMed
69.
Herman WH, Ilag LL, Johnson SL et al (2005) Clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes. Diabetes Care 28:1568–1573CrossRefPubMed
70.
Raskin P, Bode BW, Marks JB et al (2003) Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes. A randomized, parallel-group, 24-week study. Diabetes Care 26:2598–2603CrossRefPubMed
71.
Reznik Y, Cohen O, Aronson R et al (2014) Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomised open-label controlled trial. Lancet 384(9950):1265–1272CrossRefPubMed
Metadaten
Titel
Aktueller Stand der klassischen Insulinpumpentherapie
verfasst von
Dr. T. Siegmund
A. Thomas
Publikationsdatum
21.04.2017
Verlag
Springer Medizin
Erschienen in
Die Diabetologie / Ausgabe 3/2017
Print ISSN: 2731-7447
Elektronische ISSN: 2731-7455
DOI
https://doi.org/10.1007/s11428-017-0205-y

Weitere Artikel der Ausgabe 3/2017

Der Diabetologe 3/2017 Zur Ausgabe

Journal Club

Effekt der kontinuierlichen Glukosemessung bei Typ-1-Diabetes

Mitteilungen des BDE

Mitteilungen des BDE

Mitteilungen des BDI

Mitteilungen des BDI

Journal Club

Keine Reduktion kardiovaskulärer Ereignisse durch Primärprävention mittels ASS bei Patienten mit Diabetes mellitus Typ 2

Leitthema

Typ-1-Diabetes bei Kindern und Jugendlichen

Mitteilungen der DDS

Mitteilungen der DDS

Praxisempfehlungen der Deutschen Diabetes Gesellschaft

Kurz, prägnant und aktuell: Die Praxisempfehlungen der Deutschen Diabetes Gesellschaft. 

Zu den Praxisempfehlungen
Bildnachweise